13. Subsequent Events

On July 6, 2026, the Company's Compensation Committee approved special equity awards to the Company's CSO pursuant to the Company’s 2021 Incentive Plan. The awards consist of 500,000 restricted stock units ("RSUs") granted in recognition of the CSO's role in completing the Company's Private Placement that closed in March 2026, and an additional 100,000 RSUs and 400,000 non-qualified stock options granted in consideration of continued service to the Company. All awards vest quarterly over a three-year period commencing October 1, 2026, and automatically convert into, in the case of RSUs, or become exercisable for, in the case of stock options, shares of the Company’s Class B Common Stock.

On August 11, 2026, the Company announced that it has been selected as a Finalist Team in the XPRIZE Healthspan global competition, a seven-year, $101 million global competition to identify therapeutic approaches to increase human healthspan. As a result, the Company will receive a $1.0 million Milestone 2 Award to be used towards the future clinical trial required in accordance with the XPRIZE competition rules, with the opportunity to compete for the XPRIZE Grand Prize of up to $81 million, subject to the successful completion of the required clinical trial and financing thereof.